MDxHealth Receives USD 1.1 Million European Grant to Progress Bladder Cancer Program

05-May-2011 - Belgium

MDxHealth SA  announced that together with partner NovioGendix B.V., a molecular diagnostics company spun out from Radboud University Nijmegen Medical Centre (RUNMC), has received a USD 1.1 million grant from Eurotrans-Bio to progress its bladder cancer program. Eurotrans-Bio is a European Commission initiative to foster cross border research & development between companies and academia working in the biotech industry.

"This grant provides MDxHealth and NovioGendix with the necessary resources to investigate further the unique biological indicators and patterns seen in bladder cancer derived from patient samples from the existing collaboration of NovioGendix with RUNMC," explained Dr. Jan Groen, CEO of MDxHealth.

During 2011 and 2012, MDxHealth and NovioGendix will use the funds to discover and validate tumor markers for the prediction of tumor progression into the muscle in developing invasive stage of bladder cancer using DNA methylation technologies, DNA sequencing and RNA-expression profiles on clinical samples collected from bladder cancer patients at the Urology Department of RUNMC. Such predictive markers will guide the treatment decisions for the more aggressive bladder tumors.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance